The historical rank and industry rank for Ionis Pharmaceuticals's FCF Margin % or its related term are showing as below:
MEX:IONS'
s FCF Margin % Range Over the Past 10 Years
Min: -88.78 Med: -16.94 Max: 97.6
Current: -88.78
During the past 13 years, the highest FCF Margin % of Ionis Pharmaceuticals was 97.60%. The lowest was -88.78%. And the median was -16.94%.
MEX:IONS's FCF Margin % is ranked worse than 51.26% of 956
companies
in the Biotechnology industry
Industry Median: -85.21
vs MEX:IONS: -88.78
Ionis Pharmaceuticals FCF Margin % Related Terms
Ionis Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:IONS vs EXEL, BBIO, AXSM: FCF Margin % Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (MEX:IONS) has a FCF Margin % of -331.61% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ionis Pharmaceuticals and its competitors. According to the industry distribution chart, Ionis Pharmaceuticals ranks #490 out of 956 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Ionis Pharmaceuticals' FCF Margin % too high?
Ionis Pharmaceuticals' current FCF Margin % is -331.61%. Based on the distribution chart, Ionis Pharmaceuticals ranks #490 out of 956 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' FCF Margin % compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #490 out of 956 companies for FCF Margin %. This places Ionis Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current FCF Margin % is -331.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current FCF Margin % of -331.61%. The stock's GF Value™ is MXN782.91, compared to a current price of MXN1,150.00 — trading 46.9% above its estimated fair value. The current FCF Margin % is -331.61%. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current FCF Margin % is -331.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,150.00 is trading 46.9% above its estimated GF Value™ of MXN782.91.
Key valuation signals for MEX:IONS:
FCF Margin %: -331.61%
GF Value™: MXN782.91 vs. price of MXN1,150.00 (46.9% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score
Get the complete analysis for MEX:IONS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
